Mechanisms of Staphylococcus aureus survival of trimethoprim-sulfamethoxazole-induced thymineless death
mBio · 2024
DOI: 10.1128/mbio.01634-24 ↗Kurz gefasst
Fachartikel in der Zeitschrift mBio, 2024. Verfasst von Lauren J Gonsalves und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, University of Washington, Seattle, Washington, USA. Hauptthemen laut MEDLINE: Staphylococcus aureus, Anti-Bacterial Agents, Trimethoprim, Sulfamethoxazole Drug Combination, Staphylococcal Infections. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: HHS | National Institutes of Health (NIH), NIDDK NIH HHS, Cystic Fibrosis Foundation (CFF).
Abstract (Originalsprache)
Trimethoprim-sulfamethoxazole (SXT) is commonly used to treat diverse Staphylococcus aureus infections, including those associated with cystic fibrosis (CF) pulmonary disease. Studies with Escherichia coli found that SXT impairs tetrahydrofolate production, leading to DNA damage, stress response induction, and accumulation of reactive oxygen species (ROS) in a process known as thymineless death (TLD). TLD survival can occur through the uptake of exogenous thymidine, countering the effects of SXT; however, a growing body of research has implicated central metabolism as another potentially important determinant of bacterial survival of SXT and other antibiotics. Here, we conducted studies to better understand the mechanisms of TLD survival in S. aureus . We found that thymidine abundances in CF sputum were insufficient to prevent TLD of S. aureus , highlighting the importance of alternative survival mechanisms in vivo . In S. aureus cultured in vitro with SXT and low thymidine, we frequently identified adaptive mutations in genes encoding carbohydrate, nucleotide, and amino acid metabolism, supporting reduced metabolism as a common survival mechanism. Although intracellular ROS levels rose with SXT treatment in vitro , survival was not improved in the presence of ROS scavengers, unlike in E. coli . SXT challenge induced the SOS response, which was alleviated by added thymidine. Finally, an inactivating mutation in the phosphotransferase gene ptsI conferred both limitation in cellular ATP and improved survival against TLD. Collectively, these results suggest that alterations in core metabolic functions, particularly those that reduce ATP levels, predominantly confer S. aureus survival and persistence during SXT treatment, potentially identifying novel targets for co-treatment. IMPORTANCE Staphylococcus aureus is a ubiquitous organism and one of the leading causes of human infections, many of which are difficult to treat due to persistence, antibiotic resistance, or antibiotic tolerance. As our arsenal of effective antibiotics dwindles, the need for improved treatments becomes increasingly urgent, necessitating a better understanding of the precise mechanisms by which pathogens evade our most critical antimicrobial agents. Here, we report a systematic characterization of the mechanisms of S. aureus survival to treatment with the first-line antistaphylococcal antibiotic trimethoprim-sulfamethoxazole, identifying pathways and candidate targets for enhancing the efficacy of available antimicrobial agents.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Microbiology, University of Washington, Seattle, Washington, USA.
- Division of Pulmonary and Sleep Medicine, Department of Pediatrics, University of Washington, Seattle, Washington, USA.
- Pulmonary Division, Seattle Children's Hospital, Seattle, Washington, USA.
- Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA.
- Division of Critical Care Medicine, Department of Anesthesiology and Pain Medicine, University of Washington, Seattle, Washington, USA.
ORCID-Profile: Lauren J Gonsalves, Adam Waalkes, Stephen J Salipante, Daniel J Wolter
Förderung
- HHS | National Institutes of Health (NIH)
- NIDDK NIH HHS
- Cystic Fibrosis Foundation (CFF)
- NCATS NIH HHS
- NHLBI NIH HHS
Zitieren
APA
Gonsalves, L. J., Tran, A., Gardiner, T., Freeman, T., Dutta, A., Miller, C. J., McNamara, S., Waalkes, A., Long, D. R., Salipante, S. J., Hoffman, L. R., & Wolter, D. J. (2024). Mechanisms of Staphylococcus aureus survival of trimethoprim-sulfamethoxazole-induced thymineless death. mBio. https://doi.org/10.1128/mbio.01634-24
Vancouver
Gonsalves LJ, Tran A, Gardiner T, Freeman T, Dutta A, Miller CJ, et al. Mechanisms of Staphylococcus aureus survival of trimethoprim-sulfamethoxazole-induced thymineless death. mBio. 2024. doi:10.1128/mbio.01634-24
BibTeX
@article{Gonsalves2024,
author = {Gonsalves, Lauren J and Tran, Allyson and Gardiner, Tessa and Freeman, Tiia and Dutta, Angshita and Miller, Carson J and McNamara, Sharon and Waalkes, Adam and Long, Dustin R and Salipante, Stephen J and Hoffman, Lucas R and Wolter, Daniel J},
title = {Mechanisms of Staphylococcus aureus survival of trimethoprim-sulfamethoxazole-induced thymineless death},
journal = {mBio},
year = {2024},
doi = {10.1128/mbio.01634-24}
}
EUVIMED